Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/302% below fair value
$398.08−23.91 (-5.67%)
Close on Nov 18, 2026Market cap $9.20BP/E –Yield –
Madrigal Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Madrigal Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$206.29M. For fiscal 2025 it was -$190.02M. The highest annual figure on record is -$3.20M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$190.02M | – |
| FY2024 | Dec 31, 2024 | -$457.03M | – |
| FY2023 | Dec 31, 2023 | -$325.71M | – |
| FY2022 | Dec 31, 2022 | -$225.07M | – |
| FY2021 | Dec 31, 2021 | -$184.13M | – |
| FY2020 | Dec 31, 2020 | -$157.90M | – |
| FY2019 | Dec 31, 2019 | -$41.80M | – |
| FY2018 | Dec 31, 2018 | -$25.53M | – |
| FY2017 | Dec 31, 2017 | -$22.44M | – |
| FY2016 | Dec 31, 2016 | -$17.61M | – |
| FY2015 | Dec 31, 2015 | -$3.20M | – |
| FY2014 | Dec 31, 2014 | -$79.07M | – |
| FY2013 | Dec 31, 2013 | -$78.18M | – |
| FY2012 | Dec 31, 2012 | -$54.64M | – |
| FY2011 | Dec 31, 2011 | -$47.99M | – |
| FY2010 | Dec 31, 2010 | -$38.34M | – |
| FY2009 | Dec 31, 2009 | -$27.26M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$171.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$133.07M | – |
| Q3 FY2025 | Sep 30, 2025 | $78.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$88.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$104.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$67.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$135.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$149.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$80.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$85.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$75.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$84.10M | – |
| Q4 FY2022 | Dec 31, 2022 | -$58.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$59.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.46M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.97M | – |
| Q4 FY2021 | Dec 31, 2021 | -$48.16M | – |
| Q3 FY2021 | Sep 30, 2021 | -$45.61M | – |
| Q2 FY2021 | Jun 30, 2021 | -$46.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$43.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -$54.96M | – |
| Q3 FY2020 | Sep 30, 2020 | -$47.85M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$30.82M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.42M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.27M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.25M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.36M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.95M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.95M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.77M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.77M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.28M | – |
See a number that looks wrong?